Status:
RECRUITING
Sodium Glucose Co-Transporter 2 (SGLT2) and STEMI
Lead Sponsor:
Minneapolis Heart Institute Foundation
Conditions:
Heart Attack
Enlarged Heart
Eligibility:
All Genders
18-75 years
Phase:
PHASE2
Brief Summary
The purpose of the research is to determine whether a class of medication called SGLT2 inhibitor will improve the heart's function and reduce its enlargement after a heart attack. Participation in thi...
Eligibility Criteria
Inclusion
- Patients with their first STEMI (\>18 years) who underwent successful primary PCI and able to give informed consent
- At least mild LV dysfunction (LVEF \< 50%) on echocardiogram, cMRI or Left Ventriculargram following PCI
- Infarct size that is \> 10% of LV mass
- The presence of MVO that is \> 10% of infarct size
Exclusion
- Contraindication to cardiac MRI
- Life expectancy \< 1 year
- Previous CABG or Valve Surgery
- Previous STEMI
- Pregnant or planning to become pregnant or lactating women
- Cardiogenic shock (not resolved)
- Atrial fibrillation or recurrent sustained ventricular arrhythmias (excluding PVCs)
- GFR\<30 ml/min/1.73m2 or end-stage renal disease on dialysis
- Type 1 diabetes mellitus or history of diabetic ketoacidosis
- Type I or II diabetes with insulin use
- Prior intolerance of SGLT2 inhibitors
- Current use of SGLT2 inhibitors (randomized patients only)
- Contraindications to gadolinium
Key Trial Info
Start Date :
August 3 2022
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 1 2028
Estimated Enrollment :
81 Patients enrolled
Trial Details
Trial ID
NCT05305911
Start Date
August 3 2022
End Date
December 1 2028
Last Update
October 8 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Minneapolis Heart Institute Foundation
Minneapolis, Minnesota, United States, 55407